Global Fluphenazine Hydrochloride Market Size, Share and Trends Analysis Report, By Product Type (Fluphenazine Hydrochloride Tablets and Fluphenazine Hydrochloride Injection), By End-User (Hospital and Clinic), Forecast (2022-2028)

The global fluphenazine hydrochloride market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Fluphenazine hydrochloride has the capability to block postsynaptic dopamine D2 receptors in the limbic system cortical system and basal ganglia, which further results in the reduction of schizophrenia-associated hallucinations and delusions. Additionally, as a serotonin antagonist, it may inhibit lymphocyte and myeloma cell proliferation by blocking 5-hydroxytryptamine type 1B (5-ht type 1B) receptors for serotonin.
Fluphenazine Hydrochloride is the hydrochloride salt of fluphenazine, a phenothiazine with antineoplastic activity. It is a member of phenothiazines (used in the treatment of PSYCHOSES), which has a role of an anticoronaviral agent. Additionally, Fluphenazine Hydrochloride acts as an antimutagen, which can be characterized by its ability to reduce the level of free radicals. Further, at H1 and 5-HT2A receptors, fluphenazine hydrochloride acts as an inverse agonist. Moreover, as an antipsychotic compound, fluphenazine hydrochloride has been used in psychotic disorder management.
Some major players in the market include Cadila Healthcare Ltd., and Dr. Reddy’s Laboratories Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in May 2021, Cadila healthcare Ltd. is formally known as Zydus Cadila announced that the company received the approval from US Food and Drug Administration (FDA) to market Fluphenazine Hydrochloride tablets in the strengths of 1 mg, 2.5 mg, 5 mg, and 10 mg (a generic version of Prolixin Tablets). It belongs to a class of medications called phenothiazines and is also referred to as a neuroleptic. Further, the company added that the drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad, India.
Additionally, in February 2021, Dr. Reddy’s Laboratories Ltd. announced that the company is launching Fluphenazine Hydrochloride tablets, used for the management of manifestations of psychotic disorders, in the US market. The Fluphenazine Hydrochloride tablets are a therapeutic equivalent generic version of Prolixin tablets approved by the US Food and Drug Administration (FDA). The Fluphenazine Hydrochloride tablets, USP, are available in 1 mg, 2.5 mg, 5 mg, and 10 mg tablets in 100 bottle count sizes.

Market Coverage
The market number available for – 2021-2028
Base year- 2021
Forecast period- 2022-2028

Segment Covered-
By Product Type
By End-User

Regions Covered-
North America
Europe
Asia-Pacific
Rest of the World

 

Top Major Key Players:
Cadila Healthcare Ltd., and Dr. Reddy’s Laboratories Ltd., among others.

Key questions addressed by the report
What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?

Global Fluphenazine Hydrochloride Market Report by Segment
By Product Type
Fluphenazine Hydrochloride Tablets
Fluphenazine Hydrochloride Injection

By End User
Hospital
Clinic